SGS Expands Bioanalytics Capacity

The expansion at its Lincolnshire, IL, facility will double the footprint of the site’s range of services, including microbiological evaluation, drug stability studies, and medical devices testing.
Aug 14, 2017
By BioPharm International Editors

On August 8, 2017, SGS, a bio/pharmaceutical analytical and bioanalytical contract solutions provider, said it is expanding its facility in Lincolnshire in the northern suburbs of Chicago, IL. The expansion will increase the site’s current footprint from 38,500 ft2 to nearly 58,000 ft2 and is due to be completed by September 2017.

The expansion will allow the facility to increase capacity for the range of services that it offers, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will be employed to meet the demands on the laboratory.

“This investment allows us to be flexible in our approach to meeting both existing and future customer demands,” said James Nokes, vice-president, US Agriculture, Food and Life, SGS, in a company press release. “Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs. At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity, and our staff to maintain our professionalism and efficiency.”

The expansion at SGS’s Lincolnshire site follows a series of recent investments at the company’s global laboratory network. Increases in extractables and leachables capabilities have taken place at Fairfield, NJ and Shanghai, China; while French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis, respectively.

SGS has 20 laboratories that offer contract analytical and bioanalytical services in North America, Europe, and Asia. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical-trial management and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance, and regulatory consultancy.

Source: SGS

native1_300x100
lorem ipsum